Literature DB >> 12659854

Isomer-dependent daunomycin release and in vitro antitumour effect of cis-aconityl-daunomycin.

Judit Reményi1, Barbara Balázs, Sára Tóth, András Falus, Gábor Tóth, Ferenc Hudecz.   

Abstract

Two isomers of cis-aconytil-daunomycin (cAD) were isolated after the reaction of daunomycin with cis-aconitic-anhydride. The structure of the isomers was identified by MS-spectroscopy and 1H and 13C NMR experiments. In contrast with the assumptions described earlier, our results show that the two isomers belong to the cis- and trans-isomers of the alpha-monoamide of cis-aconityl-daunomycin, respectively. We found that the pH dependent daunomycin release is different for the two isomers. Comparative analysis of the in vitro antitumour effect of the isomers on c26 colon carcinoma and on MDA-MB 435P human breast carcinoma cell lines showed that cAD-1 is more potent than cAD-2, but the extent of differences is tumour cell dependent. The results of this study might be appreciated in the light of the use of acid-labile spacer for the design and preparation of protein/peptide conjugates of drugs by indicating that isomers could possess markedly different biological activity.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12659854     DOI: 10.1016/s0006-291x(03)00394-2

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  11 in total

1.  Epirubicin-[Anti-HER2/neu] Synthesized with an Epirubicin-(C13-imino)-EMCS Analog: Anti-Neoplastic Activity against Chemotherapeutic-Resistant SKBr-3 Mammary Carcinoma in Combination with Organic Selenium.

Authors:  Cody P Coyne; Toni Jones; Andrzej Sygula; John Bailey; Lesya Pinchuk
Journal:  J Cancer Ther       Date:  2011-03

2.  Synthesis of a covalent epirubicin-(C(3)-amide)-anti-HER2/neu immunochemotherapeutic utilizing a UV-photoactivated anthracycline intermediate.

Authors:  Cody P Coyne; Toni Jones; Ryan Bear
Journal:  Cancer Biother Radiopharm       Date:  2011-12-22       Impact factor: 3.099

3.  pH-responsive biodegradable assemblies containing tunable phenyl-substituted vinyl ethers for use as efficient gene delivery vehicles.

Authors:  Hee-Kwon Kim; David H Thompson; Ho Seong Jang; Yong Jin Chung; Jeroen Van den Bossche
Journal:  ACS Appl Mater Interfaces       Date:  2013-06-17       Impact factor: 9.229

4.  Synthesis of Gemcitabine-(C4-amide)-[anti-HER2/neu] Utilizing a UV-Photoactivated Gemcitabine Intermediate: Cytotoxic Anti-Neoplastic Activity against Chemotherapeutic-Resistant Mammary Adenocarcinoma SKBr-3.

Authors:  Cody P Coyne; Toni Jones; Ryan Bear
Journal:  J Cancer Ther       Date:  2012-10

5.  Acid-triggered release via dePEGylation of fusogenic liposomes mediated by heterobifunctional phenyl-substituted vinyl ethers with tunable pH-sensitivity.

Authors:  Hee-Kwon Kim; Jeroen Van den Bossche; Seok-Hee Hyun; David H Thompson
Journal:  Bioconjug Chem       Date:  2012-10-02       Impact factor: 4.774

6.  Conjugation of amino-bioactive glasses with 5-aminofluorescein as probe molecule for the development of pH sensitive stimuli-responsive biomaterials.

Authors:  Valentina Aina; Gianluca Malavasi; Claudio Magistris; Giuseppina Cerrato; Gianmario Martra; Guido Viscardi; Ledi Menabue; Gigliola Lusvardi
Journal:  J Mater Sci Mater Med       Date:  2014-04-11       Impact factor: 3.896

7.  Design, synthesis, and evaluation of pH-dependent hydrolyzable emetine analogues as treatment for prostate cancer.

Authors:  Emmanuel S Akinboye; Marc D Rosen; Samuel R Denmeade; Bernard Kwabi-Addo; Oladapo Bakare
Journal:  J Med Chem       Date:  2012-08-16       Impact factor: 7.446

8.  Preliminary study of conformation and drug release mechanism of doxorubicin-conjugated glycol chitosan, via cis-aconityl linkage, by molecular modeling.

Authors:  Thongchai Srinophakun; Jirapat Boonmee
Journal:  Int J Mol Sci       Date:  2011-03-04       Impact factor: 5.923

9.  Anti-Neoplastic Cytotoxicity of Gemcitabine-(C4-amide)-[anti-EGFR] in Dual-combination with Epirubicin-(C3-amide)-[anti-HER2/neu] against Chemotherapeutic-Resistant Mammary Adenocarcinoma (SKBr-3) and the Complementary Effect of Mebendazole.

Authors:  C P Coyne; Toni Jones; Ryan Bear
Journal:  J Cancer Res Ther Oncol       Date:  2014-04-09

Review 10.  Anticancer nanoparticulate polymer-drug conjugate.

Authors:  Quanyou Feng; Rong Tong
Journal:  Bioeng Transl Med       Date:  2016-10-28
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.